MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

Stock Information for MAIA Biotechnology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MAIA Biotechnology Inc.

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
MAIA Biotechnology Announces $1.51 Million Private Placement
MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.